Last reviewed · How we verify
Capecitabine in Combination with Cisplatin and Irinotecan — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Capecitabine in Combination with Cisplatin and Irinotecan (Capecitabine in Combination with Cisplatin and Irinotecan) — University of New Mexico.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Capecitabine in Combination with Cisplatin and Irinotecan TARGET | Capecitabine in Combination with Cisplatin and Irinotecan | University of New Mexico | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Capecitabine in Combination with Cisplatin and Irinotecan CI watch — RSS
- Capecitabine in Combination with Cisplatin and Irinotecan CI watch — Atom
- Capecitabine in Combination with Cisplatin and Irinotecan CI watch — JSON
- Capecitabine in Combination with Cisplatin and Irinotecan alone — RSS
Cite this brief
Drug Landscape (2026). Capecitabine in Combination with Cisplatin and Irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-in-combination-with-cisplatin-and-irinotecan. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab